Investor Relations
Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products using our proprietary drug formulation technologies.
We are dedicated to the continued development and commercialization of breakthrough products that better satisfy patients’ needs. Our research efforts are focused on the development of treatment options with enhanced efficacy, superior safety and convenient dosing. We have a pipeline of products in development for ourselves and our co-development collaborators.
We develop these novel products using our technology platforms:
- Bioavailability Enhancement
- Controlling Drug Release
- Dosage Form (Taste masking/ Orally disintegrating tablets)
- Drug Targeting
Our licensees have commercialized more than 40 products worldwide that utilize our technologies. We are in the process of establishing a dedicated specialty sales force in the United States that will promote niche products in target therapeutic areas. We expect that our first product to be commercialized by our sales force will be Zentase™ (formerly known as EUR-1008), if approved by the FDA.
We are a global company with research, development and manufacturing facilities in the US (Dayton, Ohio) and in Europe (Milan and Trieste, Italy; and Paris, France).
Our business was founded in Milan, Italy in 1969. From 1989 to 1999, Eurand was part of American Home Products Corporation, now Wyeth (NYSE: Wyeth). The Company became independent in 1999 as the result of a leveraged buy-out from Wyeth led by our CEO, Gearóid Faherty and affiliates of Warburg Pincus.
